Annual General Meeting appoints new Supervisory Board members

Munich, 13 June 2007. The Annual General Meeting of the Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock Exchange/Prime Standard) yesterday appointed two new members to its Supervisory Board: Professor Iris Löw-Friedrich, Executive Board member responsible for Research and Development at SCHWARZ PHARMA AG and Dr. Rüdiger Hauffe, Consultant and former CEO of SmithKline Beecham GmbH, Germany.

Dr. David Ebsworth, Dr. Georg Baur, Dr. Alexandra Goll and Dr. Friedrich von Bohlen und Halbach were reappointed to the Company's Supervisory Board. Dr. David Ebsworth was elected chairman and Dr. Georg Baur as deputy chairman of the board in the supervisory board meeting which followed the Annual General Meeting.

Professor Olaf G. Wilhelm, CEO of WILEX AG commented: "We have gained with Professor Löw-Friedrich a renowned expert in drug development who will make a significant contribution in the supervisory board. Dr. Hauffe has significantly contributed to the marketing skills of various pharmaceutical and biotechnology companies. His expertise will be of enormous support to us as we focus our efforts on the commercialisation of our products in the near future. We would like to thank both new members for joining the Supervisory Board of WILEX."

The Company also extends its thanks to the former Supervisory Board members, Dr. Jeremy Reffin of Apax Partners and Salvatore D’Orsa of Merlin Biosciences, who did not stand for re-election as neither Apax Partners or Merlin allows its employees to serve on the Supervisory Board of a listed company.

About WILEX

WILEX is a biopharmaceutical Company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body.

The portfolio includes both drug and medical product candidates ranging from research to late stage clinical development. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN.

The company's strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer. Since 13 November 2006, WILEX AG has been listed on the Frankfurt Stock Exchange in the Official Market Segment/Prime Standard.

ISIN DE0006614720/WKN 661472/Stock market symbol WL6

Contact
Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 10
81675 München
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
Email: juliane.giese@wilex.com

Back to Archive